A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Seagen Inc.
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
Aurigene Discovery Technologies Limited
Aurigene Discovery Technologies Limited
University of Pittsburgh
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Montefiore Medical Center
Astellas Pharma Inc
National Cancer Institute (NCI)
AbbVie
Travera Inc
Eli Lilly and Company
National Cancer Institute (NCI)
OncoC4, Inc.
Jazz Pharmaceuticals
Pfizer
Revolution Medicines, Inc.
USWM, LLC (dba US WorldMeds)
Alliance for Clinical Trials in Oncology
Pfizer
Cancer Research UK
Amgen
Arcus Biosciences, Inc.
AstraZeneca
SystImmune Inc.
Institut Paoli-Calmettes
Mayo Clinic
University of Wisconsin, Madison
UMC Utrecht
Neonc Technologies, Inc.
ViroMissile, Inc.
Duke University
Washington University School of Medicine
Essen Biotech
Taipei Veterans General Hospital, Taiwan
Tianjin Medical University Cancer Institute and Hospital
Thomas Jefferson University
Revolution Medicines, Inc.
Baylor College of Medicine
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Ottawa Hospital Research Institute
SystImmune Inc.
xCures
Daiichi Sankyo
University of Nebraska
Takeda